Management of CHF Exacerbation with Heart Pause

Initial Assessment and Stabilization

The European Society of Cardiology recommends performing immediate assessment with ECG and echocardiography to evaluate the severity of heart failure and characterize the heart pauses 1
The European Society of Cardiology suggests monitoring hemodynamic status with invasive arterial line if there are signs of hypoperfusion (oliguria, cold peripheries, altered mental status, elevated lactate levels, metabolic acidosis) 1
The European Society of Cardiology recommends administering fluid challenge (saline or ringer lactate, > 200 mL/15-30 min) if no signs of overt fluid overload are present 1

The European Society of Cardiology recommends administering intravenous diuretics for patients with signs of fluid overload to alleviate symptoms, improve exercise capacity, and reduce hospitalizations 3, 4
The American Heart Association suggests considering vasodilators such as intravenous nitroglycerin, nitroprusside, or nesiritide for severely symptomatic fluid overload without systemic hypotension 2
For patients with low cardiac output and signs of hypoperfusion despite adequate filling, the American College of Cardiology recommends dobutamine as the preferred inotropic agent 5

The American Heart Association recommends considering temporary pacing if pauses are causing hemodynamic compromise 2, 3
The European Society of Cardiology suggests evaluating for permanent pacemaker implantation based on the nature and frequency of pauses 3, 4
For patients with HFrEF and requiring permanent pacing for high-degree AV block, the European Society of Cardiology recommends cardiac resynchronization therapy (CRT) over right ventricular pacing regardless of NYHA class or QRS width 3, 4

The American Heart Association recommends avoiding or withdrawing medications known to adversely affect heart failure status, including most antiarrhythmic drugs and calcium channel blockers (except amlodipine) 6

The European Society of Cardiology recommends optimizing guideline-directed medical therapy (GDMT) with ACE inhibitor (or ARB if intolerant), mineralocorticoid receptor antagonist (MRA), SGLT2 inhibitor, and beta-blocker (once stabilized) for patients with HFrEF 3, 4
The European Society of Cardiology suggests considering device therapy, such as ICD for patients with symptomatic HF (NYHA class II-III) of ischemic etiology and LVEF ≤35% despite ≥3 months of optimized GDMT 3, 4
The European Society of Cardiology recommends CRT for patients with symptomatic HF, sinus rhythm, LVEF ≤35% despite GDMT, and QRS duration ≥150 ms with LBBB morphology 3, 4

The European Society of Cardiology recommends daily weight and accurate fluid balance monitoring during hospitalization 1
The European Society of Cardiology suggests daily assessment of renal function and electrolytes 1
The American College of Cardiology recommends continuous cardiac monitoring with ECG telemetry due to increased risk of arrhythmias, especially when using inotropic agents 5
The European Society of Cardiology recommends pre-discharge measurement of natriuretic peptides for post-discharge planning 1
The European Society of Cardiology suggests enrollment in a multidisciplinary HF management program to reduce the risk of HF hospitalization and improve survival 3, 4

The American Heart Association recommends avoiding long-term use of infused positive inotropic drugs except as palliation for end-stage disease 6
The American Heart Association suggests avoiding routine use of calcium channel blockers in HFrEF patients 6
The American Heart Association recommends avoiding NSAIDs as they can cause sodium and water retention and blunt the effects of diuretics 6